Clinical trial results for
previously treated
advanced bladder or
urinary tract cancer
For certain adults with previously treated advanced
bladder cancer (urothelial carcinoma)
Clinical trial results for
previously treated
advanced bladder or
urinary tract cancer
For certain adults with previously treated advanced
bladder cancer (urothelial carcinoma)
Actor portrayals.
In a clinical trial, the overall response rate to OPDIVO was looked at in 270 people with advanced bladder cancer that was previously treated with treatments that did not work or stopped working. Nearly a third of people had already been treated with multiple therapies for advanced bladder cancer, and their ages ranged from 38 to 90 years old.
Tumors disappeared completely (complete response)
Tumors shrank
(partial response)
Tumors shrank or disappeared completely (overall response)
Words to know
Overall response rate is the percentage of patients who responded to treatment. These patients saw their tumors either shrink or disappear completely.
Partial response is when a tumor reacts to treatment and shrinks.
Complete response is when a tumor reacts to treatment and disappears completely. This is the disappearance of any measurable tumors in response to treatment. This does not mean the cancer has been cured.
OPDIVO will not work for everyone. Individual results may vary.
See your recommended treatment plan and what to expect from an infusion
For adults with previously treated advanced bladder cancer (urothelial carcinoma)
OPDIVO® (nivolumab) is a prescription medicine used to treat adults with cancer of the lining of the urinary tract (including the bladder, urethra, ureters, or renal pelvis [urothelial carcinoma]) when it has spread or grown (locally advanced or metastatic) and you have tried chemotherapy that contains platinum, and it did not work or is no longer working or your cancer worsened within 12 months of treatment with chemotherapy that contains platinum, either before or after surgery to remove your cancer.
It is not known if OPDIVO is safe and effective in children younger than 12 years of age with melanoma or MSI-H or dMMR metastatic colorectal cancer.
It is not known if OPDIVO is safe and effective in children for the treatment of any other cancers.